108 related articles for article (PubMed ID: 36094691)
1. Other Primary Malignancies in Patients with Breast Cancer Who Undergo Germline Panel Testing.
Murphy BL; Yi M; Gutierrez Barrera AM; Tripathy D; Hunt KK; Arun BK
Ann Surg Oncol; 2023 Mar; 30(3):1663-1668. PubMed ID: 36094691
[TBL] [Abstract][Full Text] [Related]
2. Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis.
Sandoval RL; Leite ACR; Barbalho DM; Assad DX; Barroso R; Polidorio N; Dos Anjos CH; de Miranda AD; Ferreira ACSM; Fernandes GDS; Achatz MI
PLoS One; 2021; 16(2):e0247363. PubMed ID: 33606809
[TBL] [Abstract][Full Text] [Related]
3. Impact of Breast Cancer and Germline BRCA Pathogenic Variants on Fertility Preservation in Young Women.
Prokurotaite E; Condorelli M; Dechene J; Bouziotis J; Lambertini M; Demeestere I
Life (Basel); 2023 Apr; 13(4):. PubMed ID: 37109459
[TBL] [Abstract][Full Text] [Related]
4. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing.
Guindalini RSC; Viana DV; Kitajima JPFW; Rocha VM; López RVM; Zheng Y; Freitas É; Monteiro FPM; Valim A; Schlesinger D; Kok F; Olopade OI; Folgueira MAAK
Sci Rep; 2022 Mar; 12(1):4190. PubMed ID: 35264596
[TBL] [Abstract][Full Text] [Related]
5. Bilateral Disease Common Among Slovenian CHEK2-Positive Breast Cancer Patients.
Nizic-Kos T; Krajc M; Blatnik A; Stegel V; Skerl P; Novakovic S; Gazic B; Besic N
Ann Surg Oncol; 2021 May; 28(5):2561-2570. PubMed ID: 33030641
[TBL] [Abstract][Full Text] [Related]
6. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
[TBL] [Abstract][Full Text] [Related]
7. Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
Chavarri-Guerra Y; Villarreal-Garza C; Ferrigno AS; Mohar A; Aguilar D; Alvarez-Gomez RM; Gallardo-Alvarado L; Del Toro-Valero A; Quintero-Beulo G; Gutierrez-Delgado F; Rodriguez-Olivares JL; Ochoa-Chavez MF; Gutierrez-Seymour G; Castillo D; Herzog J; Weitzel JN
Salud Publica Mex; 2022 Feb; 64(1):41-48. PubMed ID: 35438911
[TBL] [Abstract][Full Text] [Related]
8. Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.
Borde J; Laitman Y; Blümcke B; Niederacher D; Weber-Lassalle K; Sutter C; Rump A; Arnold N; Wang-Gohrke S; Horváth J; Gehrig A; Schmidt G; Dutrannoy V; Ramser J; Hentschel J; Meindl A; Schroeder C; Wappenschmidt B; Engel C; Kuchenbaecker K; Schmutzler RK; Friedman E; Hahnen E; Ernst C
BMC Cancer; 2022 Jun; 22(1):706. PubMed ID: 35761208
[TBL] [Abstract][Full Text] [Related]
9. Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer.
Domchek SM; Jhaveri K; Patil S; Stopfer JE; Hudis C; Powers J; Stadler Z; Goldstein L; Kauff N; Khasraw M; Offit K; Nathanson KL; Robson M
Cancer; 2013 Apr; 119(7):1344-8. PubMed ID: 23165893
[TBL] [Abstract][Full Text] [Related]
10. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing.
Murphy BL; Yi M; Arun BK; Gutierrez Barrera AM; Bedrosian I
Ann Surg Oncol; 2020 Nov; 27(12):4613-4621. PubMed ID: 32720048
[TBL] [Abstract][Full Text] [Related]
11. Effects of Germline Pathogenic Variants, Cancer Subtypes, Tumor-related Characteristics, and Pregnancy-associated Diagnosis on Outcomes.
Tsai ML; Knaack M; Martone P; Krueger J; Baldinger SR; Lillemoe TJ; Susnik B; Grimm E; Olet S; Rueth N; Swenson KK
Clin Breast Cancer; 2021 Feb; 21(1):47-56. PubMed ID: 32739136
[TBL] [Abstract][Full Text] [Related]
12. Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
Fulk K; Milam MR; Li S; Yussuf A; Black MH; Chao EC; LaDuca H; Stany MP
Gynecol Oncol; 2019 Mar; 152(3):612-617. PubMed ID: 30612783
[TBL] [Abstract][Full Text] [Related]
13. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
14. The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study.
Han SA; Kim SW; Kang E; Park SK; Ahn SH; Lee MH; Nam SJ; Han W; Bae YT; Kim HA; Cho YU; Chang MC; Paik NS; Hwang KT; Kim SJ; Noh DY; Choi DH; Noh WC; Kim LS; Kim KS; Suh YJ; Lee JE; Jung Y; Moon BI; Yang JH; Son BH; Yom CK; Kim SY; Lee H; Jung SH;
Fam Cancer; 2013 Mar; 12(1):75-81. PubMed ID: 23131904
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
[TBL] [Abstract][Full Text] [Related]
16. Results from London Regional Clinical Genetics services over a 5-year period on germline
Garrett A; Talukdar S; Izatt L; Brady AF; Whyte S; Josephs KS; Shanmugasundaram M; Guillemot LS; Vakili D; Ey S; Ahmed M
J Med Genet; 2022 Jun; 59(6):554-558. PubMed ID: 34266904
[TBL] [Abstract][Full Text] [Related]
17. Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers.
Grindedal EM; Heramb C; Karsrud I; Ariansen SL; Mæhle L; Undlien DE; Norum J; Schlichting E
BMC Cancer; 2017 Jun; 17(1):438. PubMed ID: 28637432
[TBL] [Abstract][Full Text] [Related]
18. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
19. Discoveries beyond BRCA1/2: Multigene testing in an Asian multi-ethnic cohort suspected of hereditary breast cancer syndrome in the real world.
Ow SGW; Ong PY; Lee SC
PLoS One; 2019; 14(3):e0213746. PubMed ID: 30875412
[TBL] [Abstract][Full Text] [Related]
20. Management of ovarian and breast cancer risk in non-BRCA HBOC pathogenic variant carriers in a large California health care system.
Powell CB; Laurent C; Garcia C; Hoodfar E; Karlea A; Kobelka C; Lee J; Roh J; Kushi LH
Gynecol Oncol; 2022 Dec; 167(3):467-475. PubMed ID: 36220669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
